Targeting systemic metabolic dysfunction — including hypermetabolism, lipid dysregulation, and glucose intolerance — will slow ALS progression and improve survival.
Knowledge Gap Addressed
Addresses the "Systemic Metabolic Dysfunction in ALS Progression" gap — specifically, whether metabolic interventions can modify disease course.
Scientific Rationale
ALS involves significant systemic metabolic dysfunction:
Hypermetabolism: ~60% of ALS patients have elevated resting energy expenditure
Lipid alterations: Reduced HDL, elevated triglycerides correlate with faster progression
Glucose intolerance: Insulin resistance observed in subset
Muscle hypometabolism: Early metabolic defects in muscle
Metabolic dysfunction may be:
A driver of progression (via energy deficit)
A consequence (via denervation)
Both (feedback loop)
Targeting metabolism could preserve muscle function, support neural energetics, and slow progression.
Why This Matters
ALS median survival is 2-4 years
Riluzole and edaravone provide limited benefit
Metabolic interventions are low-risk
May preserve function even if not disease-modifying
Targeting systemic metabolic dysfunction — including hypermetabolism, lipid dysregulation, and glucose intolerance — will slow ALS progression and improve survival.
Knowledge Gap Addressed
Addresses the "Systemic Metabolic Dysfunction in ALS Progression" gap — specifically, whether metabolic interventions can modify disease course.
Scientific Rationale
ALS involves significant systemic metabolic dysfunction:
Hypermetabolism: ~60% of ALS patients have elevated resting energy expenditure
Lipid alterations: Reduced HDL, elevated triglycerides correlate with faster progression
Glucose intolerance: Insulin resistance observed in subset
Muscle hypometabolism: Early metabolic defects in muscle
Metabolic dysfunction may be:
A driver of progression (via energy deficit)
A consequence (via denervation)
Both (feedback loop)
Targeting metabolism could preserve muscle function, support neural energetics, and slow progression.
Why This Matters
ALS median survival is 2-4 years
Riluzole and edaravone provide limited benefit
Metabolic interventions are low-risk
May preserve function even if not disease-modifying
Validation Protocol
Study Design
Type: Multi-arm randomized controlled trial
Population:
Definite or probable ALS (Awaji or revised El Escorial)